Skip to main content
. 2021 Jan 26;93(4):2513–2522. doi: 10.1002/jmv.26797

Table 2.

Summary of patient characteristics

Author, year Age (years) Men (%) BMI (kg/m2) CAD (%) Hypertension (%) Smoking (%) Diabetes (%) Cancer (%) CKD (%)
Foy et al., 2020 17 59.6 (17.6) versus 74.6 (13.4) 53 versus 59 30.8 (6.8) versus 30.2 (7.2) 8 versus 16 23 versus 36 17 versus 22 8 versus 21
Gong et al., 2020 18 45.0 (33.0–62.0) versus 63.5 (54.5–72.0) 44.7 versus 57.1 23.4 (21.4–25.7) versus 23.4 (22.3–24.4)
Henry et al., 2020 19 44 (32–50) versus 59 (39–68) versus 66 (53–71) 68.8 versus 44.4 versus 62.5 28 (25–33) versus 26 (25–36) versus 29 (25–32) 0 versus 23.5 versus 18.8 18.8 versus 64.7 versus 68.8 25.0 versus 23.5 versus 31.3 18.8 versus 70.6 versus 31.3 0 versus 5.9 versus 18.8 0 versus 17.6 versus 18.8
Jans et al., 2020 20 60.3 (16.6) versus 68.2 (16.8) 52.4 versus 63.4 30.2 (5.7) versus 28.4 (5.4) 11.3 versus 16.1 35.7 versus 46.2 13.7 versus 23.7 6.0 versus 15.1 2.4 versus 7.5
Levy et al., 2020 21 57.2 versus 63.7 28.30 (25.10–32.60) versus 27.40 (23.90–31.70) 8.2 versus 15.4 49.6 versus 61.8 29.6 versus 35.5 6.5 versus 2.0
Lu, 2020 26 53 (43–58) versus 65 (51–74) versus 62 (52–70) versus 77 (70–81)
Lusczek et al., 2020 22 58.6 (34.8–71.3) versus 60.9 (45.9–75.4) versus 67.2 (52.9–79.0) 42.4 versus 46.6 versus 58.4 30.4 (13.4) versus 30.8 (8.2) versus 29.5 (8.9) 10.4 versus 7.2 versus 3.8 9.2 versus 11.9 versus 12.3 21.4 versus 27.7 versus 39.0
Nicholson et al., 2020 23 61 (50–71) versus 75 (66–82) 54.1 versus 66.4 14.8 versus 28.0 53.6 versus 67.3 39.8 versus 52.6 13.6 versus 25.1 13.8 versus 28.0
Wang et al., 2020 24 38 (16–62) versus 43 (28–62) 48.6 versus 60.0 2.9 versus 30.0 5.7 versus 20.0 0 versus 10.0 2.9 versus 10.0
Wu et al., 2020 25 56 (38–66) versus 62 (54–72) 56.2 versus 69.2 9.4 versus 23.4 12.5 versus 30.8 18.8 versus 20.5 3.1 versus 12.8

Abbreviations: BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.